GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surgalign Holdings Inc (OTCPK:SRGAQ) » Definitions » ROE %

Surgalign Holdings (Surgalign Holdings) ROE % : Negative Equity% (As of Mar. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Surgalign Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Surgalign Holdings's annualized net income for the quarter that ended in Mar. 2023 was $16.58 Mil. Surgalign Holdings's average Total Stockholders Equity over the quarter that ended in Mar. 2023 was $-22.33 Mil. Therefore, Surgalign Holdings's annualized ROE % for the quarter that ended in Mar. 2023 was Negative Equity%.

The historical rank and industry rank for Surgalign Holdings's ROE % or its related term are showing as below:

SRGAQ' s ROE % Range Over the Past 10 Years
Min: -1783.52   Med: -8.11   Max: 9.05
Current: -1783.52

During the past 13 years, Surgalign Holdings's highest ROE % was 9.05%. The lowest was -1,783.52%. And the median was -8.11%.

SRGAQ's ROE % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.29 vs SRGAQ: -1783.52

Surgalign Holdings ROE % Historical Data

The historical data trend for Surgalign Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surgalign Holdings ROE % Chart

Surgalign Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.72 -195.88 -115.04 -522.42 -

Surgalign Holdings Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 -97.83 -236.83 - Negative Equity

Competitive Comparison of Surgalign Holdings's ROE %

For the Medical Devices subindustry, Surgalign Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surgalign Holdings's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surgalign Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Surgalign Holdings's ROE % falls into.



Surgalign Holdings ROE % Calculation

Surgalign Holdings's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-54.605/( (8.237+-25.729)/ 2 )
=-54.605/-8.746
=N/A %

Surgalign Holdings's annualized ROE % for the quarter that ended in Mar. 2023 is calculated as

ROE %=Net Income (Q: Mar. 2023 )/( (Total Stockholders Equity (Q: Dec. 2022 )+Total Stockholders Equity (Q: Mar. 2023 ))/ count )
=16.58/( (-25.729+-18.935)/ 2 )
=16.58/-22.332
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Surgalign Holdings  (OTCPK:SRGAQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=16.58/-22.332
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(16.58 / 66.992)*(66.992 / 68.977)*(68.977 / -22.332)
=Net Margin %*Asset Turnover*Equity Multiplier
=24.75 %*0.9712*N/A
=ROA %*Equity Multiplier
=24.04 %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=16.58/-22.332
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (16.58 / 17.112) * (17.112 / -53.432) * (-53.432 / 66.992) * (66.992 / 68.977) * (68.977 / -22.332)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9689 * -0.3203 * -79.76 % * 0.9712 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Surgalign Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Surgalign Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Surgalign Holdings (Surgalign Holdings) Business Description

Traded in Other Exchanges
N/A
Address
520 Lake Cook Road, Suite 315, Deerfield, IL, USA, 60015
Surgalign Holdings Inc is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company continues to invest in clinically validated innovation to deliver the Best surgical outcomes and improve patient's lives. It markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. The U.S. market accounts for the vast majority of revenue. It has commercial and design centers in San Diego, California, and Wurmlingen, Germany.
Executives
Elizabeth A. Lapuma director 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Jill Kathleen Frizzley director P.O. BOX 1541, ONE BLUE HILL PLAZA, PEARL RIVER NY 10965
Paolo Amoruso officer: Chief Legal Officer C/O HYPERDYNAMICS CORPORATION, 12012 WICKCHESTER LANE, SUITE 475, HOUSTON TX 77079
David Lyle officer: Chief Financial Officer 6290 SEQUENCE DRIVE, SAN DIEGO CA 92121
Marc E. Mackey officer: EVP, Digital Surgery 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Terry M. Rich officer: President, Global Spine 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
William Scott Durall officer: Chief Commercial Officer 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Christopher Thunander officer: Chief Accounting Officer 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Thomas Mceachin director 11621 RESEARCH CIRCLE, ALACHUA FL 32615
Nicholas J Valeriani director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Enrico Sangiorgio officer: EVP, International 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Stuart F. Simpson director 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Pawel Lewicki director 296 WOODWARD BLVD., TULSA OK 74114
Jeffrey C Lightcap director 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019

Surgalign Holdings (Surgalign Holdings) Headlines

From GuruFocus